Genetic Technologies (Genetic Technologies) Net Margin %

: 0.00% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Genetic Technologies's Net Income for the three months ended in Dec. 2023 was $0.00 Mil. Genetic Technologies's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Genetic Technologies's net margin for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Genetic Technologies's Net Margin % or its related term are showing as below:

GENE's Net Margin % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -11.145
* Ranked among companies with meaningful Net Margin % only.

Genetic Technologies Net Margin % Historical Data

The historical data trend for Genetic Technologies's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Margin %

-26,252.94

-62,057.14

-5,818.28

-104.94

-135.28

Genetic Technologies Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-	-	-	-	-

Competitive Comparison

For the Diagnostics & Research subindustry, Genetic Technologies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetic Technologies Net Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Net Margin % distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Net Margin % falls into.

Genetic Technologies Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Genetic Technologies's Net Margin for the fiscal year that ended in Jun. 2023 is calculated as

Net Margin	=	Net Income (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-7.887	/	5.83
	=	-135.28 %

Genetic Technologies's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0
	=	%

Genetic Technologies (NAS:GENE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Genetic Technologies Net Margin % Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Technologies (Genetic Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (NAS:GENE) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

DU8:Germany GTG:Australia

Address

60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065

Website

https://www.gtglabs.com

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.